Profile data is unavailable for this security.
About the company
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
- Revenue in USD (TTM)469.82m
- Net income in USD-87.61m
- Incorporated1998
- Employees995.00
- LocationGlaukos Corp1 GLAUKOS WAYALISO VIEJO 92656United StatesUSA
- Phone+1 (949) 367-9600
- Fax+1 (949) 367-9984
- Websitehttps://www.glaukos.com
More ▼
Mergers & acquisitions
| Acquired company | GKOS:NYQ since announced | Transaction value |
|---|---|---|
| Mobius Therapeutics Inc | 32.90% | -- |
Data delayed at least 15 minutes, as of Feb 10 2026 14:50 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICU Medical Inc | 2.32bn | -7.36m | 3.75bn | 15.00k | -- | 1.76 | 19.13 | 1.62 | -0.3109 | -0.3109 | 94.30 | 86.17 | 0.552 | 2.24 | 12.70 | 154,690.90 | -0.206 | -0.2042 | -0.2351 | -0.2306 | 36.47 | 33.82 | -0.3731 | -0.3326 | 1.19 | 1.62 | 0.3829 | -- | 5.44 | 13.47 | -296.86 | -- | -3.18 | -- |
| Lantheus Holdings Inc | 1.53bn | 167.68m | 4.32bn | 808.00 | 27.39 | 3.86 | 18.62 | 2.83 | 2.38 | 2.38 | 21.90 | 16.88 | 0.7055 | 8.67 | 4.48 | 1,888,531.00 | 7.75 | 9.87 | 10.50 | 11.33 | 62.23 | 60.44 | 10.99 | 12.86 | 2.49 | -- | 0.337 | 0.00 | 18.32 | 34.59 | -4.35 | 58.06 | 29.27 | -- |
| TransMedics Group Inc | 566.35m | 90.47m | 4.66bn | 728.00 | 57.27 | 13.11 | 40.14 | 8.23 | 2.38 | 2.41 | 14.48 | 10.40 | 0.6541 | 4.65 | 6.63 | 777,958.80 | 10.45 | -5.73 | 11.37 | -6.28 | 60.28 | 62.37 | 15.97 | -11.86 | 7.13 | 31.19 | 0.5903 | -- | 82.74 | 79.64 | 241.70 | -- | 279.42 | -- |
| Teleflex Inc | 3.19bn | -327.85m | 4.69bn | 14.10k | -- | 1.23 | -- | 1.47 | -7.35 | -7.36 | 70.55 | 86.48 | 0.4154 | 2.05 | 6.00 | 226,240.30 | -4.27 | 4.58 | -4.69 | 5.01 | 53.67 | 54.77 | -10.28 | 11.38 | 1.53 | 6.78 | 0.4114 | 19.74 | 2.45 | 3.26 | -80.38 | -31.40 | 4.25 | 0.00 |
| iRhythm Holdings, Inc | 702.57m | -51.46m | 4.78bn | 2.00k | -- | 39.23 | -- | 6.81 | -1.62 | -1.62 | 22.11 | 3.78 | 0.7377 | 12.04 | 9.15 | 351,286.50 | -5.40 | -20.12 | -6.21 | -24.37 | 70.35 | 68.61 | -7.32 | -23.90 | 4.50 | -- | 0.8418 | -- | 20.13 | 22.50 | 8.20 | -- | 19.06 | -- |
| Merit Medical Systems Inc | 1.48bn | 118.43m | 4.79bn | 7.40k | 41.37 | 3.13 | 19.59 | 3.24 | 1.95 | 1.95 | 24.37 | 25.80 | 0.5898 | 2.39 | 7.38 | 199,611.90 | 4.73 | 3.49 | 5.17 | 3.93 | 48.47 | 45.37 | 8.02 | 5.65 | 2.86 | 14.41 | 0.324 | 0.00 | 7.89 | 6.40 | 27.48 | 85.69 | -14.13 | -- |
| Envista Holdings Corp | 2.72bn | 47.00m | 4.81bn | 12.30k | 106.82 | 1.55 | 29.50 | 1.77 | 0.2749 | 0.2749 | 16.10 | 18.96 | 0.4931 | 4.63 | 6.86 | -- | 0.8523 | -2.14 | 1.01 | -2.58 | 54.93 | 56.63 | 1.73 | -5.21 | 2.04 | 6.73 | 0.318 | -- | 8.32 | 7.11 | 104.20 | 2.03 | -1.03 | -- |
| Stevanato Group SpA | 1.39bn | 167.49m | 4.88bn | 5.52k | 26.24 | 2.57 | 18.25 | 3.50 | 0.6137 | 0.6137 | 5.11 | 6.27 | 0.5058 | 2.95 | 2.65 | 252,543.00 | 6.08 | 8.02 | 7.63 | 10.94 | 29.27 | 31.01 | 12.01 | 13.24 | 1.30 | 30.00 | 0.2386 | 6.82 | 1.72 | 15.53 | -19.13 | 24.61 | 33.52 | -- |
| Caris Life Sciences Inc | -100.00bn | -100.00bn | 6.29bn | -- | -- | 13.16 | -- | -- | -- | -- | -- | 1.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.36 | -- | 0.4404 | -- | 34.67 | -- | 18.22 | -- | -- | -- |
| Bruker Corp | 3.44bn | -23.70m | 6.40bn | 11.40k | -- | 2.62 | 33.18 | 1.86 | -0.1562 | -0.1562 | 22.65 | 16.06 | 0.5481 | 1.44 | 5.23 | 301,763.80 | -0.3554 | 6.80 | -0.4523 | 9.20 | 48.00 | 50.00 | -0.6485 | 9.66 | 0.8877 | 9.34 | 0.4462 | 10.87 | 13.56 | 10.19 | -73.53 | -10.52 | 9.57 | 4.56 |
| Glaukos Corp | 469.82m | -87.61m | 6.51bn | 995.00 | -- | 8.45 | -- | 13.85 | -1.55 | -1.55 | 8.28 | 13.41 | 0.4879 | 1.76 | 6.06 | 472,180.90 | -9.10 | -11.24 | -9.92 | -12.04 | 76.87 | 73.54 | -18.65 | -36.68 | 4.47 | -- | 0.0817 | -- | 21.85 | 10.10 | -8.70 | -- | 5.93 | -- |
| Masimo Corp | 1.72bn | -203.80m | 7.24bn | 3.60k | -- | 8.84 | -- | 4.22 | -3.83 | -10.61 | 31.70 | 15.25 | 0.6993 | 1.70 | 5.09 | 476,416.70 | -8.31 | 3.29 | -10.46 | 3.99 | 54.96 | 53.94 | -11.88 | 4.56 | 1.92 | 5.88 | 0.4084 | 0.00 | 2.26 | 17.43 | -474.11 | -- | -6.75 | -- |
| Avantor Inc | 6.58bn | -82.20m | 7.66bn | 13.50k | -- | 1.37 | 23.52 | 1.16 | -0.1203 | -0.1203 | 9.64 | 8.17 | 0.5364 | 5.58 | 6.07 | 487,051.80 | -0.6706 | 3.94 | -0.7693 | 4.48 | 33.13 | 33.76 | -1.25 | 6.87 | 0.9639 | 3.95 | 0.4092 | 0.00 | -2.64 | 2.35 | 121.58 | -- | 23.59 | -- |
| Bio Rad Laboratories Inc | 2.56bn | -675.90m | 7.96bn | 7.70k | -- | 1.18 | -- | 3.11 | -24.30 | -24.30 | 92.91 | 249.77 | 0.252 | 1.53 | 5.52 | 332,139.60 | -6.66 | 3.00 | -7.01 | 3.15 | 52.42 | 55.37 | -26.43 | 14.51 | 3.94 | 0.2476 | 0.1515 | 0.00 | -3.92 | 2.11 | -189.37 | -- | 13.91 | -- |
| Repligen Corp | 707.89m | 1.74m | 8.08bn | 1.78k | 5,575.92 | 3.88 | 97.33 | 11.42 | 0.0258 | 0.0258 | 12.55 | 37.01 | 0.246 | 2.00 | 5.09 | 398,138.30 | 0.0604 | 3.28 | 0.063 | 3.70 | 51.59 | 54.24 | 0.2455 | 12.37 | 7.14 | -- | 0.2052 | 0.00 | 0.3285 | 18.61 | -171.68 | -- | 5.25 | -- |
Data as of Feb 10 2026. Currency figures normalised to Glaukos Corp's reporting currency: US Dollar USD
48.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 7.81m | 13.61% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.54m | 9.67% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 3.41m | 5.94% |
| PRIMECAP Management Co.as of 30 Sep 2025 | 2.25m | 3.93% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 2.10m | 3.67% |
| AllianceBernstein LPas of 30 Sep 2025 | 1.73m | 3.02% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2025 | 1.32m | 2.30% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.32m | 2.30% |
| Westfield Capital Management Co. LPas of 30 Sep 2025 | 1.23m | 2.15% |
| William Blair Investment Management LLCas of 30 Sep 2025 | 1.09m | 1.91% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
